Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Following Treatment With Atezolizumab Plus Bevacizumab (AB) or With Another Approved Immuno-oncology Immune Checkpoint Inhibitor Combination in First-line

NCT06117891 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06117891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06117891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Following Treatment With Atezolizumab Plus Bevacizumab (AB) or With Another Approved Immuno-oncology Immune Checkpoint Inhibitor Combination in First-line
Lead sponsor
Bayer
Phase
Observational
Overall status
Active, not recruiting
Start date
November 27, 2023
Completion date
December 10, 2026
Enrollment
300 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma